Section Arrow
DAWN.NASDAQ
- Day One Biopharmaceuticals
Quotes are at least 15-min delayed:2024/05/16 14:30 EDT
Last
 16.21
-0.21 (-1.28%)
Day High 
16.49 
Prev. Close
16.42 
1-M High
18.0699 
Volume 
223.85K 
Bid
16.19
Ask
16.22
Day Low
15.91 
Open
16.49 
1-M Low
13.02 
Market Cap 
1.43B 
Currency USD 
P/E -- 
%Yield
10-SMA 16.63 
20-SMA 16.18 
50-SMA 15.4 
52-W High 18.0699 
52-W Low 9.67 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.50/-2.59
Enterprise Value
1.43B
Balance Sheet
Book Value Per Share
3.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.099999+0.022299+28.70%-- 
NBYNovaBay Pharmaceuticals0.1234+0.0189+18.09%-- 
DNAGinkgo Bioworks Holdings0.8264-0.0127-1.51%-- 
JAGXJaguar Health0.2804+0.0253+9.92%-- 
NVAXNovavax14.31+1.41+10.93%-- 
Quotes are at least 15-min delayed:2024/05/16 14:30 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.